# Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers

> **NCT02305277** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 85 (actual)

## Conditions studied

- Parkinson

## Interventions

- **DRUG:** BIA 9-1067 (clinical micronized, CM)
- **DRUG:** BIA 9-1067 (to-be-marketed, TBM)

## Key facts

- **NCT ID:** NCT02305277
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02305277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02305277, "Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02305277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*